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Topic 35 – Pulmonary hypertension
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PAH in systemic lupus erythematosus
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Introduction: Pulmonary arterial hypertension (PAH) is a rare disease charac-
terized by the progressive increase in pulmonary artery pressures, leading to right
heart failure. Systemic lupus erythematosus (SLE) is the second connectivity after
Scleroderma can be complicated by PAH. This study aims to estimate the preva-
lence of PAH in SLE, detected by echocardiography.
Materials and methods: This is a retrospective study of ten years about
80 patients with SLE fulfilling the criteria of the ACR (American College of
Rheumatology), followed in our department of internal medicine. Echocar-
diography with measurement of pulmonary artery pressure was performed in
72 patients. Above 30 mmHg mean arterial pressure was used to define PAH.
Results: Ten patients (7% of cases) had pulmonary arterial pressure greater
than 30mmHg. Two of them had lung disease (the first with emphysematous lung
and the other a lupus interstitial lung disease). Three patients had mitral insuffi-
ciency. A syndrome of anti-phospholipid antibodies (APS) was noted in four
patients (40% of cases). Five other lupus patients had isolated PAH (50% of
cases). We noted a positive anti-Sm antibody in three patients (40% of cases).
Discussion: PAH is a rare and severe complication of SLE and is a bad
prognostic factor. Its detection is based on echocardiography. PAH lupus may
be the expression of APS or secondary to pulmonary fibrosis or left valvulop-
athy. The treatment is based on corticosteroids and immunosuppressive asso-
ciation. Anticoagulants are indicated in cases of APS. 
Conclusion: Due to the severity of PAH in SLE, a screening echocardiog-
raphy should be systematically offered to patients with SLE to treat early this
serious complication and to enhance prognosis.
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Introduction: We have previously identified critical roles for the nerve
growth factor NGF in pathophysiology of pulmonary hypertension (PH). We
have here evaluated whether NGF may contribute to medial and intimal
remodelling of pulmonary arteries in vivo in PH rat models. We have also
investigated the NGF receptors and signalling pathways involved in vitro in
NGF-induced proliferation of human pulmonary arterial smooth muscle
(hPASMC) and endothelial cells (hPAEC).
Methods: Experimental PH in the rat was induced either by a single injec-
tion of monocrotaline (MCT, 60mg/kg), or after 28 days of chronic hypoxia
(CH, 0.5atm). Anti-NGF blocking antibodies (10μg/kg ip) were administered
as a preventive or a curative treatment. Pulmonary arterial pressure was
assessed after 28 days. Medial and intimal remodelling of pulmonary arteries
were then evaluated on lung sections after hematoxylin/eosin or Van Gieson
stainings. hPASMC or hPAEC proliferation was assessed by the BrdU tech-
nique, and involvement of the NGF receptors TrkA and p75NTR was studied by
both pharmalogical and SiRNA approaches.
Results: In vivo, NGF inhibition with anti-NGF blocking antibodies both
prevented and reversed medial and intimal remodelling of pulmonary arteries
in MCT and CH rats. In vitro, NGF-induced hPASMC proliferation occurred
at low concentrations and only involved TrkA/PI3-kinase dependent signalling
pathways. NGF-induced hPAEC proliferation occurred at higher concentra-
tions and involved both TrkA and p75NTR receptors activating PI3-kinase inde-
pendent/NF?B-dependent signalling pathways.
Conclusion: We show here that NGF contributes to medial and intimal
remodelling of pulmonary arteries in vivo in PH rat models. This may occur
through stimulation of both hPASMC and hPAEC proliferation, but through
distinct receptors and signalling pathways in these two different cell types,
thus suggesting that blocking both NGF receptors may be of therapeutical
interest in PH.
April 25th, Friday 2014
